The firm hopes the effort, recently described in the journal Oncotarget, will spur adoption of its testing services by oncologists, particularly in Europe, where it is determined to become a market leader.
Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
